Research chemicalResearch chemicalDissociative

3-Me-PCE

Also known as 3-Methyl-PCE

Written by enwyReviewed 4 Aug 20261 sources0 comments

3-Me-PCE (N-ethyl-3-methyl-norketamine analogue within the arylcyclohexylamine family) is a dissociative research chemical related to eticyclidine (PCE) and the 3-substituted PCP series. Like other arylcyclohexylamines it acts primarily as an NMDA receptor antagonist, producing anaesthetic, dissociative and hallucinogenic effects. Human data are minimal.

01 Overview

3-Me-PCE belongs to the arylcyclohexylamine dissociatives, a family that includes PCP, PCE, ketamine and their many analogues. It is reported to be a relatively potent dissociative but almost no formal pharmacological or safety data exist.

As an NMDA antagonist it can produce dose-dependent dissociation, anaesthesia and psychological effects, with risks of confusion, ataxia and, at high doses, a dissociative 'hole'. Grey-market purity is unreliable and its potency raises the risk of accidental overdose.

02 Mechanism

Arylcyclohexylamine NMDA receptor antagonist, reducing excitatory glutamatergic signalling to produce dissociation and anaesthesia.

03 Dosing

Tier	Dose	Route	Notes
Light	5–15 mg	Insufflated	Anecdotal.
Common	10–30 mg	Oral	Anecdotal only; potency poorly defined.

04 Effects

Effect	Magnitude	Evidence
DissociationDetachment from body and environment typical of NMDA antagonists.		Anecdotal
Anaesthesia and analgesiaReduced pain and numbing at higher doses.		Anecdotal
EuphoriaMood elevation reported at moderate doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Psychological dependence and compulsive redosingCraving and repeated dosing sprees reported with dissociatives.	Moderate	Common with heavy use	Anecdotal
Dissociative anaesthesia and injury riskAtaxia, confusion and heavy dissociation at high doses raise injury and aspiration risk.	Severe	Uncommon, dose-dependent	Anecdotal
Tachycardia and hypertensionRaised heart rate and blood pressure typical of dissociatives.	Moderate	Common	Anecdotal

06 Legal status

United States

Not scheduled by name

Possible analogue treatment under federal law. · as of Jan 2026

United Kingdom

Psychoactive Substances Act

Covered by blanket psychoactive substances legislation. · as of Jan 2026

07 References

Arylcyclohexylamine dissociatives: pharmacology and toxicologyNeuropharmacology / review literature

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.